Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Passes Below 200 Day Moving Average – Here’s Why
by Teresa Graham · The Cerbat GemElite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.49 and traded as low as $0.3753. Elite Pharmaceuticals shares last traded at $0.3875, with a volume of 220,515 shares.
Elite Pharmaceuticals Price Performance
The firm has a market cap of $410.61 million, a price-to-earnings ratio of 12.71 and a beta of 0.46. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05. The company has a 50 day moving average of $0.39 and a 200 day moving average of $0.49.
Elite Pharmaceuticals (OTCMKTS:ELTP – Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.The business had revenue of $31.59 million for the quarter.
Elite Pharmaceuticals Company Profile
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.